Integrase inhibitors: Why do we need a new drug class for HIV therapy?

4Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The introduction of integrase inhibitors as a new drug class for treatment of HIV have added a very potent and extremely well tolerated new treatment option to the HIV-armentarium. Particularly in patients with previously developed drug resistance, the availability of new active drugs offers great hope. Moreover, the in general excellent safety profile offers numerous opportunities for all lines of therapy and special patient populations. Clearly more data is needed to further explore and define the future role of integrase inhibitors in HIV-care. © I. Holzapfel Publishers 2009.

Cite

CITATION STYLE

APA

Rockstroh, J. K. (2009). Integrase inhibitors: Why do we need a new drug class for HIV therapy? European Journal of Medical Research, 14(SUPPL.3), 1–3. https://doi.org/10.1186/2047-783X-14-S3-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free